¼¼°èÀÇ ±¤°ßº´ ¹é½Å ½ÃÀå : Á¦Ç° À¯Çüº°, ¿ëµµº°, ¿¹¹æ À¯Çüº°, ÃÖÁ¾ »ç¿ëÀÚº°, ±¹°¡º°, Áö¿ªº° - »ê¾÷ ºÐ¼®, ½ÃÀå ±Ô¸ð, ½ÃÀå Á¡À¯À² ¿¹Ãø(2024-2032³â)
Rabies Vaccine Market, By Product Type, By Application, By Prophylaxis Type, By End User, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032
»óǰÄÚµå : 1514901
¸®¼­Ä¡»ç : AnalystView Market Insights
¹ßÇàÀÏ : 2024³â 06¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 367 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 3,250 £Ü 4,612,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠺Ұ¡´ÉÇϸç, ÅØ½ºÆ®ÀÇ Copy&Pasteµµ ºÒ°¡´ÉÇÕ´Ï´Ù.
US $ 4,650 £Ü 6,598,000
PDF (5 User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 5,650 £Ü 8,017,000
PDF & Excel (Enterprise User License) help
PDF & Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ ³» ¸ðµç »ç¿ëÀÚ°¡ »ç¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ®ÀÇ Copy&Paste °¡´ÉÇÕ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

º¸°í¼­ ÇÏÀ̶óÀÌÆ®

±¤°ßº´ ¹é½Å ½ÃÀå ±Ô¸ð´Â 2023³â 13¾ï 4,543¸¸ ´Þ·¯·Î 2024-2032³â¿¡ °ÉÃÄ CAGR 4.5%·Î È®´ë

±¤°ßº´ ¹é½Å ½ÃÀå - ½ÃÀå ¿ªÇÐ

¹Ý·Áµ¿¹° »çÀ° Áõ°¡¿Í ±×¿¡ µû¸¥ ¼öÀÇÇÐ Áõ°¡·Î ¹Ý·Áµ¿¹° ¿¹¹æÁ¢Á¾ÀÇ Çʿ伺ÀÌ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù.

¹Ý·Áµ¿¹° »çÀ° Áõ°¡ °æÇâ¿¡ ´õÇØ, ¼öÀÇ·á¿¡ ´ëÇÑ ÀǽÄÀÌ ³ô¾ÆÁö°í Àֱ⠶§¹®¿¡ ¹Ý·Áµ¿¹° ¿¹¹æÁ¢Á¾ÀÇ Á߿伺ÀÌ ºÎ°¢µÇ°í ÀÖ½À´Ï´Ù. ¹Ý·Áµ¿¹°À» °¡Á·¿¡°Ô ¸ÂÀÌÇÏ´Â °¡Á¤ÀÌ ´Ã¾î³²¿¡ µû¶ó ¿¹¹æ °¡´ÉÇÑ Áúº´À¸·ÎºÎÅÍ ¹Ý·Áµ¿¹°À» º¸È£ÇÏ´Â °ÍÀÌ ÃÖ¿ì¼± »çÇ×ÀÔ´Ï´Ù. ¹é½ÅÀº ±¤°ßº´, µð½ºÅÛÆÛ, ÆÄº¸¹ÙÀÌ·¯½º, °í¾çÀÌ ¹éÇ÷º´ µî ½É°¢ÇÏ°Ô Á×À» ¼ö ÀÖ´Â ´Ù¾çÇÑ Áúº´À¸·ÎºÎÅÍ ¹Ý·Áµ¿¹°À» º¸È£ÇÕ´Ï´Ù. Á¶»ç¿¡ µû¸£¸é Àεµ¿¡´Â 3,100¸¸ ¸¶¸® ÀÌ»óÀÇ ¾Ö¿Ï°ßÀÌ ÀÖ½À´Ï´Ù. ÁÖÅà ¼ÒÀ¯ÀÚ´Â ÀÓ´ëÀÚº¸´Ù ¹Ý·Áµ¿¹°À» Ű¿ì´Â °æÇâÀÌ °­ÇÕ´Ï´Ù. Àεµ¿¡¼­´Â 11%ÀÇ »ç¶÷ÀÌ Àû¾îµµ 4¸¶¸®ÀÇ ¹Ý·Áµ¿¹°À» Ű¿ì°í ÀÖ½À´Ï´Ù. ¹Ý·Áµ¿¹° »çÀ°ÀÌ °è¼Ó Áõ°¡ÇÏ´Â µ¿¾È, ¿¹¹æ Á¢Á¾ÀÇ Á߿伺Àº ¹Ý·Áµ¿¹°°ú ±× µ¿¹ÝÀÚÀÇ °Ç°­À» º¸È£ÇÏ´Â µ¥ ÇʼöÀûÀÔ´Ï´Ù. Á¤±âÀû ÀÎ ¿¹¹æ Á¢Á¾Àº Ã¥ÀÓÀÖ´Â ¹Ý·Áµ¿¹° ÄɾîÀÇ Áß¿äÇÑ ¿ä¼ÒÀ̸ç, ¹Ý·Áµ¿¹°ÀÌ ´õ °Ç°­ÇÏ°í ¿À·¡ »ìµµ·Ï º¸ÀåÇÏ´Â µ¿½Ã¿¡ °øÁß º¸°ÇÀ» º¸È£ÇÕ´Ï´Ù.

±¤°ßº´ ¹é½Å ½ÃÀå - ÁÖ¿ä ÀλçÀÌÆ®

¿ì¸®ÀÇ ¸®¼­Ä¡ ¾Ö³Î¸®½ºÆ®ÀÇ ºÐ¼®¿¡ µû¸£¸é ¼¼°è ½ÃÀåÀº ¿¹Ãø ±â°£(2024-2032³â)¿¡ ¾à 4.5%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)·Î ¸Å³â ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ°í ÀÖ½À´Ï´Ù.

¿¹¹æ¹ýº°·Î´Â ³ëÃâ Àü ¿¹¹æÀÌ 2023³â ÃÖ´ë ½ÃÀå Á¡À¯À²À» ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

ÃÖÁ¾ »ç¿ëÀÚº°·Î 2023³â º´¿øÀÌ ÁÖ¿ä À¯ÇüÀ̾ú½À´Ï´Ù.

¿ëµµº°·Î 2023³â¿¡´Â µ¿¹°ÀÌ ÁÖ¿ä À¯ÇüÀ̾ú½À´Ï´Ù.

Áö¿ªº°·Î´Â ºÏ¹Ì°¡ 2023³â ÁÖ¿ä ¼öÀÍ¿øÀ̾ú½À´Ï´Ù.

±¤°ßº´ ¹é½Å ½ÃÀå - ¼¼ºÐÈ­ ºÐ¼® :

¼¼°è ±¤°ßº´ ¹é½Å ½ÃÀåÀº Á¦Ç° À¯Çü, ¿ëµµ, ¿¹¹æ¹ý, ÃÖÁ¾ »ç¿ëÀÚ ¹× Áö¿ª¿¡ µû¶ó ¼¼ºÐÈ­µË´Ï´Ù.

½ÃÀåÀº ¿¹¹æ¹ý¿¡ µû¶ó µÎ °¡Áö ¹üÁÖ·Î ³ª´¹´Ï´Ù. ³ëÃâ Àü ¿¹¹æ°ú ³ëÃâ ÈÄ ¿¹¹æ. Àå±â ¿¹¹æÀº ³ëÃâ Àü ¿¹¹æÁ¦¿¡ ÀÇÇØ Á¦°øµÇ¸ç, ±¤°ßº´ ³ëÃâ °¡´É¼ºÀÌ ÀÖ´Â °æ¿ì ³ëÃâ ÈÄ ½Å¼ÓÇÑ Ä¡·áÀÇ Çʿ伺À» °¨¼Ò½Ãŵ´Ï´Ù. ³ëÃâ ÈÄ ¿¹¹æ ºñ¿ëÀ» °í·ÁÇϸé, ÀÌ Àå±â ¿¹¹æÀº Àå±âÀûÀ¸·Î ºñ¿ë È¿À²ÀûÀÎ °ÍÀ¸·Î ÀÔÁõµÉ ¼ö ÀÖ½À´Ï´Ù.

½ÃÀåÀº ÃÖÁ¾ »ç¿ëÀÚ¿¡ ÀÇÇØ ¼¼ °¡Áö ¹üÁÖ·Î ³ª´¹´Ï´Ù. º´¿ø, µ¿¹° º´¿ø, ±âŸ. ¼¼°è ¹Ý·Áµ¿¹° »çÀ°·üÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ±¤°ßº´ ¿¹¹æ Á¢Á¾À» Æ÷ÇÔÇÑ ¼öÀÇÇÐ ¼­ºñ½ºÀÇ ¿ä±¸°¡ Ä¿Áö°í ÀÖ½À´Ï´Ù. µ¿¹° º´¿øÀÌ °³¿Í °í¾çÀ̸¦ Æ÷ÇÔÇÑ ¹Ý·Áµ¿¹°¿¡°Ô Á¦°øÇÏ´Â ¿¹¹æ ÀÇ·á¿¡´Â Á¤±âÀû ÀÎ ¹é½Å Á¢Á¾ ÇÁ·Î±×·¥ÀÌ Æ÷ÇԵ˴ϴÙ. ¸é¿ªÀ» À¯ÁöÇϱâ À§Çؼ­´Â Á¤±âÀû ÀÎ ¹é½Å Á¢Á¾ÀÌ ÇʼöÀûÀÔ´Ï´Ù. ºÎ½ºÅÍ Á¢Á¾ÀÇ ºóµµ´Â »ç¿ëÇÏ´Â ¹é½Å ¹× Áö¿ª ¹ý·ü¿¡ µû¶ó ´Ù¸£Áö¸¸ ÀϹÝÀûÀ¸·Î ¿¬ 1ȸ¿¡¼­ 3³â¿¡ 1ȸÀÔ´Ï´Ù.

±¤°ßº´ ¹é½Å ½ÃÀå - Áö¸®Àû ÅëÂû

³ôÀº Á¦Ç° µµÀÔ·ü, ÁÖ¿ä Á¦Á¶¾÷üÀÇ Á¸Àç, ±¤°ßº´ ¹é½Å Á¢Á¾À» ÃËÁøÇÏ´Â Á¤ºÎÀÇ Ä·ÆäÀο¡ ÀÇÇØ ºÏ¹Ì´Â ±¤°ßº´ ¹é½ÅÀÇ Áß¿äÇÑ ½ÃÀåÀÌ µÇ°í ÀÖ½À´Ï´Ù. ÁÖ¿ä °øÇå±¹Àº ¹Ì±¹, ij³ª´Ù, ¸ß½ÃÄÚÀÇ 3°³±¹À¸·Î, ¹Ì±¹Àº ±× Á¤±³ÇÑ ÀÇ·á ½Ã½ºÅÛ°ú ³ôÀº ÀÎÁöµµ¿¡ ÀÇÇØ ¸®µåÇϰí ÀÖ½À´Ï´Ù. ºÏ¹Ì°¡ ½ÃÀå Á¡À¯À²·Î ¼±µµÇϰí ÀÖ´Â ÀÌÀ¯´Â Áúº´ ¿¹¹æ Àü·«À¸·Î ¹é½ÅÀÌ ³Î¸® »ç¿ëµÇ°í ÀÖÀ¸¸ç ÀÇ·á »ê¾÷ÀÇ ¿¬±¸ °³¹ß ȯ°æÀÌ °®Ãß¾îÁ® Àֱ⠶§¹®ÀÔ´Ï´Ù. Centres for Disease Prevention and PreventionÀÇ ÃßÁ¤¿¡ µû¸£¸é, ±¤°ßº´ÀÇ ¹ß°ß°ú ¿¹¹æ°ú °ü·ÃµÈ ¹Ì±¹ÀÇ ¿¬°£ ÀÇ·áºñ´Â 3¾ï ´Þ·¯¸¦ ³Ñ¾î¼¹½À´Ï´Ù.

±¤°ßº´ ¹é½Å ½ÃÀå - °æÀï ±¸µµ :

Sanofi(ÇÁ¶û½º), Merck &Co.Inc., Pfizer(¹Ì±¹), VBI Vaccines Inc.(¹Ì±¹), CSC Pharmaceuticals International, Bio-Med Pvt. Ltd.(¹Ì±¹), Bavarian Nordic(¹Ì±¹), Solvay(¹Ì±¹), Informa plc.(¹Ì±¹)¿Í °°Àº ´ë±â¾÷ÀÌ ½ÃÀå¿¡ ÁøÀÔÇϰí ÀÖ½À´Ï´Ù. ½ÃÀå ÀüüÀÇ ¼ºÀåÀ» Áö¿øÇϱâ À§ÇØ ÀÌ·¯ÇÑ »ê¾÷ ÁøÃâ ±â¾÷Àº »ý»ê ´É·Â È®´ë, M&A, ÆÄÆ®³Ê½Ê, ½ÅÁ¦Ç° °³¹ß, Àμö µî ¿©·¯ °¡Áö ¹æ¹ýÀ» ½Ç½ÃÇß½À´Ï´Ù. °Ô´Ù°¡ ºÐ¼® ±â°£ µ¿¾È ÁÖ¿ä »ê¾÷ ÁøÃâ±â¾÷ÀÇ ¿¬±¸°³¹ß ÅõÀÚ°¡ È®´ëµÇ°í ½ÃÀå È®´ë¸¦ Áö¿øÇÒ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù. ¿¹¸¦ µé¾î, 2024³â 3¿ù ±¤°ßº´ ¹Ú¸ê¿¡ ´ëÇÑ Áö¼ÓÀûÀÎ Çå½ÅÀÇ ÀÏȯÀ¸·Î Merck&Co.(´ºÀúÁöÁÖ ¶ó¿þÀÌ)ÀÇ ºÎ¹®ÀÎ Merck Animal Health´Â Worldwide Veterinary Service(WVS)ÀÇ Mission Rabies ÇÁ·Î±×·¥¿¡ NOBIVAC(R) ±¤°ßº´ ¹é½ÅÀ» ±âºÎÇß½À´Ï´Ù. ÇâÈÄ 5³â°£ ÀÌ ±âºÎ±ÝÀº ÀÌ ºñ¿µ¸® ´Üü°¡ ¸Å³â ÇÊ¿ä·Î ÇÏ´Â ±¤°ßº´ ¹é½ÅÀ» °è¼Ó Áö¿øÇÕ´Ï´Ù.

¸ñÂ÷

Á¦1Àå ±¤°ßº´ ¹é½Å ½ÃÀå °³¿ä

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ±¤°ßº´ ¹é½ÅÀÇ ÁÖ¿ä ½ÃÀå µ¿Çâ

Á¦4Àå ±¤°ßº´ ¹é½Å »ê¾÷ Á¶»ç

Á¦5Àå ±¤°ßº´ ¹é½Å ½ÃÀå : COVID-19ÀÇ ¿µÇ⠺м®

Á¦6Àå ±¤°ßº´ ¹é½Å ½ÃÀå »óȲ

Á¦7Àå ±¤°ßº´ ¹é½Å ½ÃÀå-Á¦Ç° À¯Çüº°

Á¦8Àå ±¤°ßº´ ¹é½Å ½ÃÀå-¿ëµµº°

Á¦9Àå ±¤°ßº´ ¹é½Å ½ÃÀå-¿¹¹æ¹ýº°

Á¦10Àå ±¤°ßº´ ¹é½Å ½ÃÀå - ÃÖÁ¾ »ç¿ëÀÚº°

Á¦11Àå ±¤°ßº´ ¹é½Å ½ÃÀå-Áö¿ªº°

Á¦12Àå ÁÖ¿ä º¥´õ ºÐ¼® - ±¤°ßº´ ¹é½Å ¾÷°è

Á¦13Àå ¾Ö³Î¸®½ºÆ®ÀÇ Àü¹æÀ§ Àü¸Á

JHS
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

REPORT HIGHLIGHT

Rabies Vaccine Market size was valued at USD 1,345.43 million in 2023, expanding at a CAGR of 4.5% from 2024 to 2032.

Growing pet ownership and the corresponding rise in veterinary care emphasize the need for pet vaccinations, thereby expanding the market. Ongoing research and development leading to improved vaccines with better efficacy, longer protection, and fewer side effects stimulate market demand. Increased awareness about rabies prevention and the importance of vaccination through educational campaigns positively impacts market growth. However, there are concerns over potential side effects and adverse reactions that can deter individuals from getting vaccinated.

Rabies Vaccine Market- Market Dynamics

Growing pet ownership and the corresponding rise in veterinary care emphasize the need for pet vaccinations

The growing trend in pet ownership, coupled with an increasing awareness of veterinary care, underscores the importance of pet vaccinations. As more households welcome pets into their families, ensuring these animals are protected against preventable diseases becomes a top priority. Vaccines protect pets from a variety of serious and potentially fatal diseases, such as rabies, distemper, parvovirus, and feline leukemia. According to the survey, there are over 31 million pet dogs in India. Homeowners are more likely to own pets than renters: 58% of homeowners have a dog and 36% have a cat versus 39% and 29% of renters respectively. 11% of people in India own at least four pets. As pet ownership continues to rise, the emphasis on vaccinations is essential for safeguarding the health of pets and their human companions. Regular vaccinations are a vital component of responsible pet care, ensuring that pets live longer, healthier lives while also protecting public health.

Rabies Vaccine Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 4.5% over the forecast period (2024-2032)

Based on Prophylaxis Type segmentation, Pre-Exposure Prophylaxis was predicted to show maximum market share in the year 2023

Based on application segmentation, Hospitals were the leading type in 2023

Based on application segmentation, the animal was the leading type in 2023

Based on region, North America was the leading revenue generator in 2023

Rabies Vaccine Market- Segmentation Analysis:

The Global Rabies Vaccine Market is segmented based on Product Type, Application, Prophylaxis Type, End User, and Region.

The market is divided into two categories based on prophylaxis type: Pre-Exposure Prophylaxis, and Post-Exposure Prophylaxis. Long-term protection is provided by pre-exposure prophylaxis, which lessens the requirement for prompt post-exposure care in the event of a possible rabies exposure. When post-exposure prophylaxis costs are taken into account, this long-term protection may prove to be cost-effective in the long run.

The market is divided into three categories based on end-users: Hospitals, Veterinary clinics, and Others. The increased global pet ownership rate has led to a larger need for veterinary services, including rabies vaccinations. The preventative care that veterinary clinics offer to pets, including dogs and cats, includes routine vaccination programs. Regular booster vaccinations are essential for maintaining immunity. The frequency of boosters depends on the vaccine used and local laws, but it generally ranges from annually to every three years.

Rabies Vaccine Market- Geographical Insights

Due to a high rate of product introductions, the existence of major manufacturers, and government campaigns to promote rabies vaccination, North America is a substantial market for rabies vaccines. Three major contributors are the United States, Canada, and Mexico with the United States leading because of its sophisticated healthcare system and high degree of awareness. North America leads the area in terms of market share due to the widespread use of vaccines as a disease prevention strategy and a conducive environment for research and development in the healthcare industry. According to estimates from the Centres for Disease Prevention and Prevention, the annual health costs in America related to the detection and prevention of rabies have surpassed USD 300 million.

Rabies Vaccine Market- Competitive Landscape:

Sanofi (France), Merck & Co. Inc., Pfizer (USA), VBI Vaccines Inc. (USA), CSC Pharmaceuticals International, Bio-Med Pvt. Ltd., Bavarian Nordic (USA), Solvay (USA), Informa plc. (USA), and other major players are among those involved in the market. To support the market's overall growth, these industry players are implementing several methods, including capacity expansion, mergers and acquisitions, partnerships, new product development, and acquisitions. Additionally, during the analysis period, growing investments made in research & development by the major industry players would support market expansion. For instance, In March 2024, As part of its ongoing commitment to eradicating rabies, Merck Animal Health, a division of Merck & Co., Inc., Rahway, N.J., donated NOBIVAC(R) rabies vaccines to the Worldwide Veterinary Service (WVS) Mission Rabies program. Over the next five years, the donations will continue to support this non-profit organization's annual rabies vaccine requirements.

Recent Developments:

In February 2024, US-based biotech Replicate Bioscience announced positive preliminary data where its self-replicating RNA (srRNA) rabies vaccine, RBI-4000 achieved a strong immune response against the rabies virus.

In March 2022, The University of Oxford and the Ifakara Health Institute announced the vaccination of the first participants in a Phase Ib/II trial testing a novel rabies vaccine in human volunteers in Tanzania.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL RABIES VACCINE MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

Serum Institute of India Pvt. Ltd

Novartis AG

Cadila Pharmaceuticals

Merck & Co., Inc.

Sanofi

ADS Diagnostic Ltd

GSK plc

Berna Biotech Pharma GmbH

AstraZeneca

Others

GLOBAL RABIES VACCINE MARKET, BY PRODUCT TYPE- MARKET ANALYSIS, 2019 - 2032

GLOBAL RABIES VACCINE MARKET, BY APPLICATION- MARKET ANALYSIS, 2019 - 2032

GLOBAL RABIES VACCINE MARKET, BY PROPHYLAXIS TYPE - MARKET ANALYSIS, 2019 - 2032

GLOBAL RABIES VACCINE MARKET, BY END USER- MARKET ANALYSIS, 2019 - 2032

GLOBAL RABIES VACCINE MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

Table of Contents

1. Rabies Vaccine Market Overview

2. Executive Summary

3. Rabies Vaccine Key Market Trends

4. Rabies Vaccine Industry Study

5. Rabies Vaccine Market: COVID-19 Impact Analysis

6. Rabies Vaccine Market Landscape

7. Rabies Vaccine Market - By Product Type

8. Rabies Vaccine Market - By Application

9. Rabies Vaccine Market - By Prophylaxis Type

10. Rabies Vaccine Market - By End User

11. Rabies Vaccine Market- By Geography

12. Key Vendor Analysis- Rabies Vaccine Industry

13. 360 Degree Analyst View

14. Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â